SAR-20347 is primarily recognized for its role as a potent and selective inhibitor of tyrosine kinase receptors, particularly targeting TAM family receptors (Tyro3, Axl, and MerTK). Its application is significant in the field of oncology, where it is studied for its potential to inhibit cancer cell proliferation and survival. By blocking these receptors, SAR-20347 disrupts signaling pathways that promote tumor growth, metastasis, and immune evasion, making it a promising candidate for cancer therapy, especially in resistant or aggressive cancers. Additionally, it is being explored for its potential in modulating the tumor microenvironment and enhancing the efficacy of immunotherapies. Research is ongoing to further understand its therapeutic potential and optimize its use in clinical settings.